CPChayanisa Phutiyothin

Chayanisa Phutiyothin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chayanisa Phutiyothin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhanced Efficacy of Sandblasted, Large-Grit, Alkaline-Etched (SLA) Titanium Surfaces Combined with Plasma Treatment and Secretory Leukocyte Protease Inhibitor (SLPI) Coating in Promoting Osteoblast Activity and Reducing Bacterial Adhesion

    by Wannapat Chouyratchakarn, Nattikan Thongjui, Chayanisa Phutiyothin, Onnicha Srisopar, Surasak Tangkamonsri, Chakrit Wiboonsuntharangkoon, Pakorn Sang-Ngam, Norrapon Vichiansan, Nithi Atthi, Chayarop Supanchart, et al.

    The clinical success rate of titanium (Ti) implants is significantly reduced in elderly patients and by implant-associated bacterial infections. Thus, Ti surfaces were modified using sandblasted large-grit alkaline etching (SLA), argon-nonthermal plasma treatment, and recombinant human secretory leukocyte protease inhibitor (rhSLPI) coating. This study evaluated surface characteristics, human fetal osteoblast (hFOB 1.19) activities, and antibacterial efficacy. The modified surfaces exhibited increased roughness and hydrophilicity compared to Ti. The SBPTi-rhSLPI enhanced 7-day protein retention on the surface. While Ti promoted higher cell proliferation, the modified groups demonstrated superior cell adhesion and mineralization. Specifically, SBPTi-rhSLPI showed the highest cytoplasmic spreading, adhesion-related gene expression (Itgα1, Itgα2, Itgα5, and Itgβ1), and mineralization. Additionally, rhSLPI-coated groups effectively reduced the adhesion of both S. aureus and E. coli. In conclusion, combining SLA modification, argon plasma treatment, and rhSLPI coating provides enhanced effects. This combined approach significantly enhances osteoblast adhesion and mineralization while possessing antibacterial potential, which could be a promising strategy to improve implant success rates.

  • Open Access

    Recombinant human secretory leukocyte protease inhibitor (rhSLPI) coated titanium enhanced human osteoblast adhesion and differentiation

    by Radchanon Leelasukseree, Wannapat Chouyratchakarn, Chayanisa Phutiyothin, Faprathan Pikwong, Onnicha Srisopar, Phornsawat Baipaywad, Suruk Udomsom, Podsawee Mongkolpathumrat, Chayarop Supanchart, Sarawut Kumphune

    Osseointegration is vital to success in orthopedic and dental reconstructions with implanted materials. The bone matrix or cells—particularly osteoblasts—are required to achieve functional contact on the implant surface. Osteoblast induction is therefore essential for osteogenesis to occur. Enhancement of osteoblast adhesion, proliferation, and differentiation, particularly by implant surface modifications, have been found challenging to develop. Secretory Leukocyte Protease Inhibitor (SLPI), a cation ionic protein with anti-inflammatory and anti-bacterial activities, showed activation in osteoblast proliferation and differentiation. However, the effects of coating recombinant human (rh) SLPI on a titanium alloy surface on human osteoblast adhesion, proliferation, and differentiation has never been investigated. In this study, titanium alloys (Ti–6Al–4V) were coated with rhSLPI, while human osteoblast adhesion, proliferation, differentiation, actin cytoskeletal organization, and gene expressions involved in cell adhesion and differentiation were investigated. The results indicate that coating titanium with 10–100 µg/ml rhSLPI enhanced the physical properties of the Ti surface and enhanced human osteoblast (hFOB 1.19) cell adhesion, activated actin dynamic, enhanced adhesive forces, upregulated integrins α1, α2, and α5, enhanced cell proliferation, mineralization, alkaline phosphatase activity, and upregulated ALP, OCN, and Runx2. This is the first study to demonstrate that coating SLPI on titanium surfaces enhances osseointegration and could be a candidate molecule for surface modification in medical implants.


  • Development of nanoparticles for delivering recombinant human secretory leukocytes protease inhibitor (rhSLPI) for reducing vascular endothelial cell injury

    by Chayanisa Phutiyothin, Wannapat Chouyratchakarn, Faprathan Pikwong, Pensak Jantrawut, Phornsawat Baipaywad, Sarawut Kumphune